Mer­ck KGaA inks ADC dis­cov­ery deal with AI tech­bio worth up to $1.4B in mile­stones

Mer­ck KGaA is part­ner­ing with AI tech­bio Caris Dis­cov­ery to iden­ti­fy and de­vel­op new an­ti­body-drug con­ju­gates in a move that could ex­pand the Ger­man com­pa­ny’s on­col­o­gy port­fo­lio.

Irv­ing, TX-based Caris will get an undis­closed up­front pay­ment and re­search fund­ing and is al­so el­i­gi­ble for up to $1.4 bil­lion in mile­stones and tiered roy­al­ties on sales, per a Thurs­day re­lease. Mer­ck KGaA will take re­spon­si­bil­i­ty for pre­clin­i­cal re­search through com­mer­cial­iza­tion for AD­Cs against up to 15 se­lect­ed tar­gets, for which it will get glob­al li­cens­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER